In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.
CB-06036 Overview
CB06-036 is in development for the treatment of hepatitis B infection. It works by targeting Toll-like receptor 8 (TLR8). It is administered by the oral route.
Overview of Shanghai Zhimeng Biopharmaceuticals
Shanghai Zhimeng Biopharmaceutical Co., Ltd. is a biotechnology company focused on discovering and developing innovative therapies for the treatment of chronic hepatitis B virus infection and neurological diseases. The company is headquartered in China.
For complete information on CB-06036 drug-specific PTSR and LoA scores, purchase the report here.
Desde
The gold standard in business intelligence.
GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.
GlobalData, a leading provider of industry intelligence, provided the underlying data, research and analysis used to write this article.
GlobalData’s Likelihood of Approval Analysis tool dynamically assesses and predicts the likelihood of a drug advancing to the next phase of clinical development (PTSR), as well as the likelihood of drug approval (LoA). This is based on a combination of machine learning and proprietary algorithms used to process data points from various databases in GlobalData’s Pharmaceutical Intelligence Center.